Literature DB >> 23653000

CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL).

Aparecida de Lourdes Perim1, Roberta Losi Guembarovski, Julie Massayo Maeda Oda, Leandra Fiori Lopes, Carolina Batista Ariza, Marla Karine Amarante, Maria Helena Pelegrinelli Fungaro, Karen Brajão de Oliveira, Maria Angelica Ehara Watanabe.   

Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Genetic polymorphisms in the 3'UTR region of the CXCL12 (rs1801157) and TP53 codon 72 (rs1042522) genes may contribute to susceptibility to childhood ALL because they affect some important processes, such as metastasis regulation and tumor suppression. Thus the objective of the present study was to detect the frequency of two genetic polymorphisms in ALL patients and controls and to add information their impact on genetic susceptibility and prognosis. The CXCL12 and TP53 polymorphisms were tested in 54 ALL child patients and in 58 controls by restriction fragment length polymerase chain reaction and allelic specific chain reaction techniques, respectively. The frequencies of both allelic variants were higher in ALL patients than in the controls and indicated a positive association: OR = 2.44; 95 % CI 1.05-5.64 for CXCL12 and OR = 2.20; 95 % CI 1.03-4.70 for TP53. Furthermore, when the two genetic variants were analyzed together, they increased significantly more than fivefold the risk of this neoplasia development (OR = 5.24; 95 % CI 1.39-19.75), indicating their potential as susceptibility markers for ALL disease and the relevance of the allelic variant combination to increased risk of developing malignant tumors. Future studies may indicate a larger panel of genes involved in susceptibility of childhood ALL and other hematological neoplasias.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23653000     DOI: 10.1007/s11033-013-2551-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  27 in total

1.  Primary structure polymorphism at amino acid residue 72 of human p53.

Authors:  G J Matlashewski; S Tuck; D Pim; P Lamb; J Schneider; L V Crawford
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

2.  TP53 gene polymorphism: importance to cancer, ethnicity and birth weight in a Brazilian cohort.

Authors:  Helena S Thurow; Ricardo Haack; Fernando P Hartwig; Isabel O De Oliveira; Odir A Dellagostin; Denise P Gigante; Bernardo L Horta; Tiago Collares; Fabiana K Seixas
Journal:  J Biosci       Date:  2011-12       Impact factor: 1.826

Review 3.  Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance.

Authors:  Carlos Graux
Journal:  Transfus Apher Sci       Date:  2011-02-25       Impact factor: 1.764

Review 4.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

5.  CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients.

Authors:  Karen Brajão de Oliveira; Roberta Losi Guembarovski; Julie Massayo Maeda Oda; Mário Sérgio Mantovani; Clisia Mara Carrera; Edna Maria Vissoci Reiche; Julio Cesar Voltarelli; Ana Cristina da Silva do Amaral Herrera; Maria Angelica Ehara Watanabe
Journal:  Cytokine       Date:  2011-05-17       Impact factor: 3.861

Review 6.  Architecture of inherited susceptibility to common cancer.

Authors:  Olivia Fletcher; Richard S Houlston
Journal:  Nat Rev Cancer       Date:  2010-05       Impact factor: 60.716

Review 7.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

8.  CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

Authors:  Karen Brajão de Oliveira; Julie Massayo Maeda Oda; Julio Cesar Voltarelli; Thiago Franco Nasser; Mario Augusto Ono; Thiago Cezar Fujita; Tiemi Matsuo; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 9.  Childhood leukemias--current status and future perspective.

Authors:  C H Pui
Journal:  Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi       Date:  1995 Sep-Oct

Review 10.  Contribution of bone microenvironment to leukemogenesis and leukemia progression.

Authors:  F Ayala; R Dewar; M Kieran; R Kalluri
Journal:  Leukemia       Date:  2009-09-03       Impact factor: 11.528

View more
  11 in total

1.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

Review 2.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.

Authors:  F Guo; Y Wang; J Liu; S C Mok; F Xue; W Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 3.  CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.

Authors:  Aparecida de Lourdes Perim; Marla Karine Amarante; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Cell Mol Life Sci       Date:  2015-01-09       Impact factor: 9.261

4.  The CXCL12 G801A polymorphism is associated with cancer risk: a meta-analysis.

Authors:  Ke Zhu; Benchun Jiang; Rong Hu; Ying Yang; Miao Miao; Yingchun Li; Zhuogang Liu
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

5.  Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies.

Authors:  Xin Tian; Shundong Dai; Jing Sun; Shenyi Jiang; Youhong Jiang
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

6.  Wilms' tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes.

Authors:  Patricia Midori Murobushi Ozawa; Carolina Batista Ariza; Roberta Losi-Guembarovski; Alda Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Bruna Karina Banin-Hirata; Marina Okuyama Kishima; Diego Lima Petenuci; Maria Angelica Ehara Watanabe
Journal:  Mol Cell Pediatr       Date:  2016-11-10

7.  Absence of Association between CCR5 rs333 Polymorphism and Childhood Acute Lymphoblastic Leukemia.

Authors:  Carlos Eduardo Coral de Oliveira; Marla Karine Amarante; Aparecida de Lourdes Perim; Patricia Midori Murobushi Ozawa; Carlos Hiroki; Glauco Akelinghton Freire Vitiello; Roberta Losi Guembarovski; Maria Angelica Ehara Watanabe
Journal:  Adv Hematol       Date:  2014-04-13

8.  The SDF-1 rs1801157 Polymorphism is Associated with Cancer Risk: An Update Pooled Analysis and FPRP Test of 17,876 Participants.

Authors:  Xiang Tong; Yao Ma; Huajiang Deng; Xixi Wang; Sitong Liu; Zhipeng Yan; Shifeng Peng; Hong Fan
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

9.  Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells.

Authors:  Ha-Yon Kim; So-Yeon Lee; Deog-Young Kim; Ji-Young Moon; Yoon-Seok Choi; Ik-Chan Song; Hyo-Jin Lee; Hwan-Jung Yun; Samyong Kim; Deog-Yeon Jo
Journal:  Blood Res       Date:  2015-12-21

Review 10.  The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis.

Authors:  Xiao-Lan Ruan; Sheng Li; Xiang-Yu Meng; Peiliang Geng; Qing-Ping Gao; Xu-Bin Ao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.